Activation and activators of SIRT5
The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the K m of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5. The invention also provides a method for treating a urea cycle disorder in a mammal, as well as a method of assaying a sirtuin modulator.
1. A method of increasing a deacetylase activity of SIRT5, wherein the method comprises contacting SIRT5 with an agent that binds SIRT5 and reduces the K m of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5,
wherein the agent is a compound of the formula (I):
wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted acyloxy, trialkylsilyl, optionally substituted alkyl, optionally substituted alkylaryl, phosphate, diphosphate, and triphosphate,
R 3 is hydrogen and R 4 is hydroxyl, R 3 and R 4 are fluoro, or R 3 is hydrogen and R 4 is chloro,
R 5 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, F, Cl, Br, I, CF 3 , optionally substituted alkoxy, optionally substituted aryl, NO 2 , optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted acyloxy, hydroxy, mercapto, and optionally substituted thioamido, or any of R 5 and R 6 taken together, R 6 and R 7 taken together, R 7 and R 8 taken together, or R 8 and R 9 taken together, form a 5- or 6-membered saturated or unsaturated ring,
R 6 is COR 10 or B(OR 11 ) 2 ,
R 10 is selected from the group consisting of hydrogen, hydroxy, alkoxy, and aryloxy, and
R 11 is hydrogen or C 1 -C 6 alkyl.
2. The method of claim 1 , wherein R 1 is hydrogen or phosphate and R 2 is hydrogen.
3. The method of claim 1 , wherein R 6 is COR 10 and R 10 is alkoxy or aryloxy.
4. The method of claim 1 , wherein the SIRT5 is present in a eukaryotic cell.
5. A method for treating a urea cycle disorder in a mammal, which method comprises administering to a mammal in need of treatment a therapeutically effective amount of a compound of the formula (I):
wherein R 1 and R 2 are independently selected from the group consisting of hydrogen, optionally substituted acyl, optionally substituted acyloxy, trialkylsilyl, optionally substituted alkyl, optionally substituted alkylaryl, phosphate, diphosphate, and triphosphate,
R 3 is hydrogen and R 4 is hydroxyl, R 3 and R 4 are fluoro, or R 3 is hydrogen and R 4 is chloro,
R 5 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, F, Cl, Br, I, CF 3 , optionally substituted alkoxy, optionally substituted aryl, NO 2 , optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted acyloxy, hydroxy, mercapto, and optionally substituted thioamido, or any of R 5 and R 6 taken together, R 6 and R 7 taken together, R 7 and R 8 taken together, or R 8 and R 9 taken together, form a 5- or 6-membered saturated or unsaturated ring,
R 6 is COR 10 or B(OR 11 ) 2 ,
R 10 is selected from the group consisting of hydrogen, hydroxy, alkoxy, and aryloxy, and
R 11 is hydrogen or C 1 -C 6 alkyl,
thereby treating a urea cycle disorder in the mammal.
6. The method of claim 5 , wherein R 1 is hydrogen or phosphate and R 2 is hydrogen.
7. The method of claim 5 , wherein R 6 is COR 10 and R 10 is alkoxy or aryloxy.
8. The method of claim 5 , wherein the urea cycle disorder is selected from the group consisting of ornithine transcarbamoylase deficiency, carbamoyl phosphate synthetase deficiency, argininosuccinic aciduria, argininemia, hyperornithinemia, hyperammonemia, homocitrullinuria syndrome, lysinuric protein intolerance, citrullinemia, and N-acetylglutamate synthase deficiency.
9. The method of claim 8 , wherein the urea cycle disorder is hyperammonemia.
10. A method of increasing a deacetylase activity of SIRT5, wherein the method comprises contacting SIRT5 with an agent that binds SIRT5 and reduces the K m of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5,
wherein the agent is a compound of the formula (I):
wherein R 1 and R 2 are independently selected from the group consisting of optionally substituted acyl, optionally substituted acyloxy, trialkylsilyl, optionally substituted alkyl, and optionally substituted alkylaryl,
R 3 and R 4 are both fluoro,
R 5 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, F, Cl, Br, I, CF 3 , optionally substituted alkoxy, optionally substituted aryl, NO 2 , optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted acyloxy, hydroxy, mercapto, and optionally substituted thioamido, or any of R 5 and R 6 taken together, R 6 and R 7 taken together, R 7 and R 8 taken together, or R 8 and R 9 taken together, form a 5- or 6-membered saturated or unsaturated ring,
R 6 is COR 10 ,
R 10 is amino, alkylamino, or dialkylamino, and
R 11 is hydrogen or C 1 -C 6 alkyl.
11. The method of claim 10 , wherein the SIRT5 is present in a eukaryotic cell.
12. A method for treating a urea cycle disorder in a mammal, which method comprises administering to a mammal in need of treatment a therapeutically effective amount of a compound of the formula (I):
wherein R 1 and R 2 are independently selected from the group consisting of optionally substituted acyl, optionally substituted acyloxy, trialkylsilyl, optionally substituted alkyl, and optionally substituted alkylaryl,
R 3 and R 4 are both fluoro,
R 5 , R 7 , R 8 , and R 9 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, F, Cl, Br, I, CF 3 , optionally substituted alkoxy, optionally substituted aryl, NO 2 , optionally substituted alkylthio, optionally substituted amino, optionally substituted acylamino, optionally substituted arylamino, optionally substituted acylthio, optionally substituted acyl, optionally substituted acyloxy, hydroxy, mercapto, and optionally substituted thioamido, or any of R 5 and R 6 taken together, R 6 and R 7 taken together, R 7 and R 8 taken together, or R 8 and R 9 taken together, form a 5- or 6-membered saturated or unsaturated ring,
R 6 is COR 10 ,
R 10 is amino, alkylamino, or dialkylamino, and
R 11 is hydrogen or C 1 -C 6 alkyl,
thereby treating a urea cycle disorder in the mammal.
13. The method of claim 12 , wherein the urea cycle disorder is selected from the group consisting of ornithine transcarbamoylase deficiency, carbamoyl phosphate synthetase deficiency, argininosuccinic aciduria, argininemia, hyperornithinemia, hyperammonemia, homocitrullinuria syndrome, lysinuric protein intolerance, citrullinemia, and N-acetylglutamate synthase deficiency.
14. The method of claim 13 , wherein the urea cycle disorder is hyperammonemia.